• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tenax Therapeutics Inc.

    8/30/24 4:20:02 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TENX alert in real time by email
    S-8 1 tenx_s8.htm S-8 tenx_s8.htm

    As filed with the Securities and Exchange Commission on August 30, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    TENAX THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    26-2593535

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

     

    101 Glen Lennox Drive, Suite 300

    Chapel Hill, North Carolina

     

    27517

    (Address of Principal Executive Offices)

     

    (Zip Code)

      

    Tenax Therapeutics, Inc. 2022 Stock Incentive Plan, As Amended

    (Full title of the plan)

     

    Christopher T. Giordano

    President and Chief Executive Officer

    101 Glen Lennox Drive, Suite 300

    Chapel Hill, North Carolina 27517

    (919) 855-2100

    (Name, address and telephone number, including area code, of agent for service)

     

    With copies to:

    Donald Reynolds

    S. Halle Vakani

    Lorna A. Knick

    Wyrick Robbins Yates & Ponton LLP

    4101 Lake Boone Trail, Suite 300

    Raleigh, North Carolina 27607

    (919) 781-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.☐

     

     

     

     

    EXPLANATORY NOTE:

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 is being filed for the purpose of registering an additional 400,000 shares of Tenax Therapeutics, Inc.’s (the “Registrant”) common stock to be issued pursuant to the Tenax Therapeutics, Inc. 2022 Stock Incentive Plan, as amended (the “2022 Plan”) and for which a Registration Statement of the Registrant on Form S-8 relating to the 2022 Plan is effective.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF

    REGISTRATION STATEMENT ON FORM S-8

     

    The contents of the Registration Statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the “Commission”) on August 12, 2022 (File No. 333-266833) relating to the 2022 Plan, as modified or superseded pursuant to Rule 412 under the Securities Act of 1933, as amended, are incorporated herein by reference.

     

     
    2

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    The following table sets forth the exhibits either filed herewith or incorporated herein by reference:

     

    Exhibit No.

     

    Description

    4.1.1

     

    Certificate of Incorporation of Oxygen Biotherapeutics, Inc. (incorporated by reference to Exhibit 3.01 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 30, 2008).

    4.1.2

     

    Certificate of Amendment of the Certificate of Incorporation, effective November 9, 2009 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on November 13, 2009).

    4.1.3

     

    Certificate of Amendment of the Certificate of Incorporation, effective May 10, 2013 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 15, 2013).

    4.1.4

     

    Certificate of Amendment of the Certificate of Incorporation, effective September 19, 2014 (incorporated by reference to Exhibit 3.4 to the Registrant’s Quarterly Report on Form 10-Q filed with the Commission on December 15, 2014).

    4.1.5

     

    Certificate of Amendment of the Certificate of Incorporation, effective February 23, 2018 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on February 23, 2018).

    4.1.6

     

    Certificate of Amendment to Certificate of Incorporation, as amended of Tenax Therapeutics, Inc., effective January 4, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 4, 2023).

    4.1.7

     

    Certificate of Amendment of Certificate of Incorporation of Tenax Therapeutics, Inc., as amended (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 5, 2024).

    4.2

     

    Fourth Amended and Restated Bylaws of Tenax Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on August 15, 2023).

    5.1*

     

    Opinion of Wyrick Robbins Yates & Ponton LLP.

    23.1*

     

    Consent of Independent Registered Public Accounting Firm Cherry Bekaert LLP.

    23.2

     

    Consent of Wyrick Robbins Yates & Ponton LLP (contained in Exhibit 5.1).

    24.1

     

    Power of Attorney (contained on signature page).

    99.1

     

    Tenax Therapeutics, Inc. 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 10, 2022).

    99.2

     

    Amendment No. 1 to the Tenax Therapeutics, Inc. 2022 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 13, 2024).

    99.3

     

    Form of Tenax Therapeutics, Inc. Notice of Stock Option Grant and Award Agreement (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 10, 2022).

    107*

     

    Filing Fee Table

    _____________

    * Filed herewith.

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Chapel Hill, State of North Carolina on August 30, 2024.

     

     

    TENAX THERAPEUTICS, INC.

     

     

     

     

     

    By:

    /s/ Christopher T. Giordano

     

     

     

    Christopher T. Giordano

     

     

     

    President and Chief Executive Officer

    (Principal Executive Officer)

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS that the undersigned officers and directors of the Registrant do hereby constitute and appoint Christopher T. Giordano, President and Chief Executive Officer, and Lawrence R. Hoffman, Interim Chief Financial Officer, and each of them, the lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments that said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated below.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Christopher T. Giordano

     

    President, Chief Executive Officer and Director

    (principal executive officer)

     

    August 30, 2024

    Christopher T. Giordano

     

     

     

     

     

     

    /s/ Lawrence R. Hoffman

     

    Interim Chief Financial Officer

     

    August 30, 2024

    Lawrence R. Hoffman

     

    (principal financial officer and principal accounting officer)

     

     

     

     

     

     

     

    /s/ Gerald Proehl

     

    Chairman of the Board and Director

     

    August 30, 2024

    Gerald Proehl

     

     

     

     

     

     

    /s/ June Almenoff, MD

     

    Director

     

    August 30, 2024

    June Almenoff, MD

     

     

     

     

     

     

    /s/ Michael Davidson, MD

     

    Director

     

    August 30, 2024

    Michael Davidson, MD

     

     

     

     

    /s/ Declan Doogan, MD

     

    Director

     

    August 30, 2024

    Declan Doogan, MD

     

     

     

     

     

     

    /s/ Robyn M. Hunter

     

    Director

     

    August 30, 2024

    Robyn M. Hunter

     

     

     

     

     

     

    /s/ Stuart Rich, MD

     

    Director

     

    August 30, 2024

    Stuart Rich, MD

     

     

     

     

     

     
    4

      

    Get the next $TENX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TENX

    DatePrice TargetRatingAnalyst
    9/8/2025$20.00Overweight
    Piper Sandler
    10/24/2024$16.00Outperform
    Leerink Partners
    10/14/2024$16.00Buy
    Guggenheim
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $TENX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

    CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY. Details of presentation:Format: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer; Douglas Randall, Chief Business OfficerDate and Time: February 11, 2026, at 12:30 p.m. ET The live and archived webcast of the p

    2/4/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

    Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL demonstrated the trial is powered at well

    12/17/25 9:16:49 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics to Participate in Upcoming Investor Conferences

    CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences: 8th Annual Evercore Healthcare ConferenceFormat: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical OfficerDate and Time: December 2, 2025, at 4:15 p.m. ET Piper Sandler 37th Annual Healthcare ConferenceFormat: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer, Stuar

    11/25/25 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Interim CFO Mcgauley Thomas

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    2/3/26 5:57:56 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Davidson Michael H.

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    1/13/26 9:49:18 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Giordano Christopher Thomas

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    1/13/26 9:37:38 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    SEC Filings

    View All

    Tenax Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    1/9/26 4:33:28 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    12/17/25 5:00:18 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Tenax Therapeutics Inc.

    10-Q - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    11/12/25 4:40:02 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Tenax Therapeutics with a new price target

    Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00

    9/8/25 8:59:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Tenax Therapeutics with a new price target

    Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00

    10/24/24 6:39:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Tenax Therapeutics with a new price target

    Guggenheim initiated coverage of Tenax Therapeutics with a rating of Buy and set a new price target of $16.00

    10/14/24 7:43:13 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Leadership Updates

    Live Leadership Updates

    View All

    Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

    CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). "We are

    1/22/25 8:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

    -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

    11/4/24 7:30:00 AM ET
    $ATNM
    $AVTX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

    CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company's PH-HFpEF Scientific Advisory Board (SAB). "We are thrilled to welcome Dr. Butler to our Scientific Advisory Board," said Stuart Rich, M.D., Chief Medical Officer of Tenax Therapeutics. "Javed is regarded as one of the most eminent clinical trialists in cardiovascular medicine, and he joins three highly distinguished cardiovascular lead

    11/17/23 8:30:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

    SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 12:21:05 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

    SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/13/24 5:35:29 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Financials

    Live finance-specific insights

    View All

    Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended September 30, 2025 and provided an update on its recent corporate progress. "We c

    11/12/25 4:05:00 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq

    5/17/21 5:15:00 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

    MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i

    1/19/21 7:45:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care